Green light for Novavax's anti-Covid vaccine

Green light for the anti-Covid vaccine from Novavax

Hello, Welcome to the TopWhich News site! I will present you all the details of Green light for the anti-Covid vaccine from Novavax here.

Green light for Novavax’s anti-Covid vaccine

Green light for the anti-Covid vaccine from Novavax We have explained the details of the news, step by step, below. Green light for Novavax’s anti-Covid vaccine Keep reading our news. Here are all the details on the subject.

Green light for the anti-Covid vaccine from Novavax

Updated 20 December 2021, 15: 19

The $pean regulator authorizes the use of the remedy of the American manufacturer, which thus becomes the fifth vaccine recommended in the EU.

Switzerland has already signed a contract with the American manufacturer for 6 million doses.

AFP The $pean Medicines Agency (EMA) gave the green light on Monday for Novavax’s anti-Covid vaccine, using more conventional technology than those used for already licensed vaccines, which could reduce skepticism among the unvaccinated. The American firm’s Nuvaxovid vaccine thus becomes “the fifth vaccine recommended in the EU to prevent Covid – 18 ”at the most of 18 years, the EMA pointed out in a statement.

As a reminder, Switzerland had already signed a contract with the American manufacturer last February, for the purchase of 6 million doses.

Two injections

Nuvaxovid is a so-called “subunit” vaccine, based on proteins that trigger an immune response, without viruses. The technology is similar to that used in the decades-old hepatitis B and pertussis vaccines that are widely used around the world.

For company CEO Stanley C. Erck, the vaccine “could help overcome major barriers to global immunization, including challenges of global distribution and vaccine reluctance.”

Nuvaxovid is given as two injections, usually into the muscle of the upper arm, 3 weeks apart. The side effects seen with the serum in the studies were generally mild or moderate, and resolved within a few days of vaccination.

The $pean Commission, which had concluded a contract with Novavax for the advance purchase of 90 millions doses of its vaccine, will now speed up the decision-making process to allow this vaccine to be included in vaccination programs across the EU.

Solid data

“After a thorough evaluation, the EMA’s Committee for Medicinal Products for Human Use (CHMP) concluded by consensus that the data on the vaccine were robust and met EU criteria for efficacy, safety and efficacy. quality ”, underlined the EMA.

The main clinical trials – one in Great Britain and one in the United States and Mexico – involving more than 20 00 people, showed between 89 and 90% effectiveness in reducing the number of symptomatic cases of Covid.

The EMA also noted that “the original strain of SARS-CoV-2 and some variants of concern such as Alpha and Beta were the most common viral strains circulating when studies were underway.”

“There is currently limited data on the efficacy of Nuvaxovid against other variants of concern, including Omicron,” the EMA noted, indicating that “the safety and efficacy of the vaccine will continue to be monitored as and as it is used across the EU ”.

The American company had for its part recognized that it “was evaluating its vaccine against the Omicron variant” and was still working on a specific version to combat this particularly contagious variant.

Novavax’s vaccine “will support vaccination campaigns in EU member states during a crucial phase of the pandemic,” praised the EMA as warnings mount around the world over the spread of the Omicron variant particularly contagious.


[sidebar name=”Footer 3″]